INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Paper

Nanotechnology-Based Diagnosis and Treatment of Fungal Infections

Priyanka Kachave*, Anuja Pharne, Vedanti Dawange

Sinhgad Institute of Pharmacy Narhe Pune College

ARTICLE INFO

Published: 29 Jun. 2025
Keywords:
Nanotechnology, Fungal infections, Nanoparticles, Antifungal therapy, Diagnostics, Drug delivery, Nanosensors
DOI:
10.5281/zenodo.15767356

ABSTRACT

Fungal infections are an increasing concern in clinical settings, particularly among immunocompromised individuals. These infections, caused by pathogens such as Candida, Aspergillus, and Cryptococcus, are often difficult to diagnose and treat due to limitations in conventional antifungal therapies and diagnostics. Emerging drug resistance and toxicity further compound these challenges. Nanotechnology offers innovative solutions for both the diagnosis and treatment of fungal infections. This review explores how nanomaterials, including metal nanoparticles, liposomes, dendrimers, and quantum dots, are revolutionizing fungal infection management. We also discuss the current challenges in clinical translation and propose future directions for research and development in this area.

INTRODUCTION

Fungal infections are a global health problem, esp ecially in immunocompromised individuals such as physicians, organ transplant recipients, or peop le with HIV/AIDS (1). These infections, primarily caused by pathogenic species like *Candida*, *Aspergillus*, *Cryptococcus*, and *Histoplasma*, can lead to a wide range of clinical manifestations, from superficial skin infections to life-threatening systemic conditions (2). The incidence of fungal infections has increased due to the emergence of various types of antifungal drugs that reduce the effectiveness of antifungal medications. (3).

***Corresponding Author:** Priyanka Kachave
Address: *Sinhgad Institute of Pharmacy Narhe Pune College*
Email ✉: priyankakachave769@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



Figure: 1. Nanotechnology-based drug delivery systems. (20)

1.1 Limitations of Conventional Antifungal Treatments and Diagnostics

Conventional antibiotics, which generally include polyenes (e.g. amphotericin B), azoles (e.g. fluconazole), and echinocandins (e.g. caspofungin), often have many limitations, including high toxicity, poor solubility, limited bioavailability, and the occurrence of drug reactions (4). Amphotericin B is still one of the most effective antibiotics, but its use is limited due to its nephrotoxicity (5). Furthermore, fungal pathogens have resisted azoles, the most commonly used antifungals, which has driven an urgent need for alternative treatment options (6). In addition to medical problems, fungal diseases also face significant limitations. Current methods such as culture methods, polymerase chain reaction (PCR), and serological tests are often time-consuming and not sensitive enough to detect early. They cannot distinguish between colonization and infection (7). Considering these limitations, there is a need for new methods in the diagnosis and treatment of fungal diseases. Nanotechnology offers a revolutionary tool to solve these complex problems in this context.

1.2 Role of Nanotechnology in Addressing Fungal Infections

Nanotechnology is manipulating matter at the atomic, molecular, or supramolecular level, usually at 1–100 nanometres. Artifacts of this size have chemical, physical, and biological properties that differ from larger materials (8). These properties make nanomaterials ideal candidates for many biomedical applications, including drug delivery, diagnosis, and treatment. Nanotechnology offers new solutions for fungal diseases that overcome the limitations of antibiotics and diagnostic methods. Nanoparticles can be designed to increase drug solubility, select fungal pathogens, penetrate biofilms, and increase drug bioavailability (9). Clinical applications of nanotechnology are equally promising. Nanosensors provide rapid, sensitive, and specific detection of fungal diseases, enabling early diagnosis and treatment. (10).

1.3 Classification of Nanomaterials in Fungal Infection Management

Nanomaterials used in fungal infection management can be broadly classified based on their composition and application. Each class of nanomaterial offers distinct advantages and challenges depending on the context of their use.

1.3.1 Organic Nanomaterials

Organic nanomaterials mainly include carbon-based structures such as liposomes, dendrimers, micelles, and polymeric nanoparticles. These materials are biodegradable and biocompatible, making them ideal for drug delivery.

- **Liposomes** are spherical vesicles composed of lipid bilayers, capable of encapsulating both hydrophilic and hydrophobic drugs. Liposomal formulations such as liposomal amphotericin B (AmBisome) have lower toxicity compared to drug formulations when administered clinically. (11). Liposomes can also be functionalized with specific targeting ligands to deliver antibodies to the site of infection and reduce side effects. (12).

- **Polymeric nanoparticles** are versatile carriers that can be engineered to release drugs in a controlled manner. These nanoparticles have been used to deliver antibiotics such as itraconazole, increasing the solubility and bioavailability of the drug. (13). Due to their biocompatibility and tunable release properties, polymeric nanoparticles are promising tools for antifungal therapy.

- **Dendrimers** are highly branched synthetic polymers that can be functionalized with multiple ligands or drugs. Dendrimers exhibit several effects that enable targeted drug delivery and increase solubility and cellular uptake (14). Research into dendrimer-based formulations continues with a focus on increasing their specificity and reducing potential toxicity.

1.3.2 Inorganic Nanomaterials

Inorganic nanomaterials are made of metal or met al oxide nanoparticles such as silver, gold, zinc o xide, etc. These materials can prevent many funga l diseases due to their ability to produce reactive oxygen species (ROS) and disrupt fungal cell wal ls and membranes (15).

- **Silver nanoparticles (AgNPs)** are one of the most studied inorganic nanomaterials in the field of antibiotic use. AgNPs exhibit broad-spectrum antifungal activity by inducing oxidative stress and disrupting the integrity of fungal cell membranes (16). AgNPs also prevent biofilm formation, which is a major challenge in the treatment of persistent fungal infections (20). AgNPs are effective against bacteria such as Candida auris (16).

- **Gold nanoparticles (AuNPs)** can be used in combination with phototherapy to selectively target and kill fungal pathogens due to their photothermal properties (17). When working with antibodies or target molecules, AuNPs show greater selectivity and efficacy, reducing the potential for side effects.

- **Zinc oxide nanoparticles (ZnO NPs)** have also emerged as effective antibacterial agents. ZnO NPs induce oxidative stress and disrupt fungal biofilms, which is important for the control of persistent infections caused by Candida and Cryptococcus (18). These nanoparticles have the potential for therapeutic and preventive applications.

1.3.3 Hybrid Nanomaterials

Hybrid nanomaterials combine organic and inorganic components to create multifunctional

systems with enhanced antifungal properties. Nanomaterials can be developed to have diagnostic and therapeutic functions, allowing for the detection and treatment of fungal diseases. (13).

- **Metal-organic frameworks (MOFs**) are hybrid nanostructures containing metal ions coordinated with organic ligands. MOFs have been used to encapsulate antibodies and deliver drugs in a controlled manner, with the added benefit of ROS release to promote drug resistance (18).
- **Nanocomposites** are another example of hybrid materials that combine an organic matrix with inorganic nanoparticles. For example, polymer composites loaded with silver nanoparticles have been used to increase the stability and antifungal activity of conventional drugs (19). These hybrid systems provide a versatile platform for the development of next-generation vaccines.

1.4 Applications of Nanotechnology in Fungal Infections

The application of nanotechnology in fungal infection management can be broadly divided into two major categories: **diagnostics** and **therapeutics**.

1.4.1 Nanotechnology in Diagnostics

Early diagnosis of fungal infections is important to improve patient outcomes, especially in immunocompromised individuals, as early diagnosis can prevent infection. Nanotechnology is leading to the development of unique and specific diagnostic tools, such as nanosensors that can detect fungal pathogens at low concentrations. Proteins and other biomarkers can provide rapid and accurate diagnosis, even in the early stages of disease.

1.4.2 Nanotechnology in Therapeutics

Nanoparticle-based drug delivery systems are revolutionizing the way antifungal drugs are administered. By encapsulating antifungal agents in nanocarriers, such as liposomes, dendrimers, and polymeric nanoparticles, it is possible to enhance the solubility, stability, and bioavailability of these drugs. Nanocarriers can also be engineered to target fungal cells selectively, reducing off-target toxicity and improving therapeutic efficacy (20). The ability of nanoparticles to overcome drug resistance mechanisms further highlights their potential as next-generation antifungal therapies. Mechanisms of action, and the potential challenges of integrating nanotechnology into clinical practice.

2. Current Limitations of Traditional Diagnostics and Antifungal Treatments

2.1 Limitations in Diagnostics

Fungal infections are notoriously difficult to diagnose due to the non-specific symptoms they present and the limitations of current diagnostic methods (20). Traditional culture techniques, while still considered the gold standard, are slow, taking up to several days or even weeks to yield results. Serological tests, though faster, often lack the sensitivity needed for early detection, particularly in immunocompromised patients where fungal loads may be low (20). PCR-based molecular diagnostics have improved the speed and accuracy of fungal detection; however, these methods are still expensive and require specialized equipment, limiting their accessibility in resource-constrained settings (21). Moreover, traditional diagnostic methods often fail to differentiate between colonization and infection, leading to unnecessary or delayed treatments.



Figure: 2. Nanosensors for Fungal Detection. (21)

2.2 Challenges in Antifungal Therapy

Antifungal therapies are currently based on three main drug classes: polyenes, azoles, and echinocandins. All groups face significant challenges. Polyenes, such as amphotericin B, are effective against many fungi but are severely nephrotoxic. Azole drugs, such as fluconazole, are widely used but have become ineffective due to the increasing number of antifungal agents. Echinocandins target fungal cell wall synthesis and have limited oral bioavailability, limiting them to intravenous injection (22). In addition, biofilms formed by fungal pathogens are difficult to treat. Biofilms protect fungal cells from antibiotics, allowing them to survive high doses of antibiotics (23). The emergence of antifungal agents such as C. auris adds to these challenges, highlighting the need for new therapeutic strategies (25).

3. Nanotechnology for the Diagnosis of Fungal Infections

Nanotechnology holds promise for addressing the limitations of traditional diagnostic methods. Nanomaterials exhibit unique properties due to their size and large surface area, making them ideal candidates for the development of sensitive devices and specialized diagnostics. Nanosensors are of particular interest due to their ability to detect fungal infections at an early stage.

3.1 Biosensors Based on Quantum Dots

Quantum dots (QDs) are semiconductor nanoparticles with unique optical properties, such as size-tunable light emission and resistance to photobleaching, making them ideal for diagnostic applications (28). Quantum dot-based biosensors have been developed to detect fungal diseases and

enable accurate and specific information with optimal, sensitive, and specific clinical samples.

The sensor achieved specificity for Candida species with bacterial DNA detection as low as 10 pg/mL, far exceeding the sensitivity of traditional PCR-based diagnostics (29). This technology has the potential to improve early detection of fungal infections, especially in individuals with early immunity.

3.2 Nanosensors for Fungal Detection

For example, graphene oxide nanosheets have been developed to detect Candida bacteria in clinical samples. These nanosheets show excellent sensitivity and can detect fungal infections at levels as low as 10^2 CFU/mL, allowing for early and accurate diagnosis. Another example is the use of quantum dots conjugated to antibodies to prevent Aspergillus infection in immunocompromised patients (29). The use of high fluorescence quantum dots provides important results in the diagnostic process by allowing immediate monitoring of fungal diseases. Nanosensors are sensitive devices that can detect low concentrations of biomarkers, making them useful for early detection of fungal infections (36). These sensors typically use materials such as graphene oxide, carbon nanotubes, and quantum dots, which have been shown to detect fungal pathogens with high sensitivity and specificity (36).

Table 1: Comparison of Traditional and Nanotechnology-Based Diagnostic Methods for Fungal Infections

Method	Sensitivity	Specificity	Time to Result	Cost	Clinical Utility
Culture	Moderate	High	Days to weeks	Low	Standard clinical use
Serological tests	High	Moderate	Hours to days	Moderate	Detects antibodies
PCR-based diagnostics	High	High	Hours	High	Detects fungal DNA
Nanosensors	Very High	Very High	Minutes to hours	High	Early detection

4. Nanotechnology in the Treatment of Fungal Infections

Nanoparticles hold great promise in overcoming the limitations of antibiotic therapy. Due to their small size and tunable surface properties, nanoparticles can be designed to improve the solubility, stability, and bioavailability of antibiotics, while also reducing toxicity and improving target specificity.

4.1 Nanoparticle-Based Drug Delivery Systems

Nanoparticles such as liposomes, dendrimers, and polymeric nanoparticles are widely investigated as pharmaceutical agents for antimicrobial activity. These nanocarriers improve the pharmacokinetics of anti-inflammatory drugs, allowing for greater delivery and reducing side effects. For example, liposomes have been used to encapsulate amphotericin B, one of the most potent antibiotics available. Liposomal amphotericin B (AmBisome) reduces formulation-associated nephrotoxicity while maintaining efficacy. Similarly, polymeric nanoparticles have been used to improve the solubility and bioavailability of poorly water-soluble antifungal agents such as itraconazole, thereby increasing their therapeutic efficacy (38). Chemically synthesized polymers provide another promising platform for drug resistance. Dendrimers can be functionalized with antibiotics and targeting ligands due to their distinct orientations, allowing for specific targeting of fungal pathogens. In addition, dendrimers can increase the solubility of hydrophobic drugs, improving their bioavailability and therapeutic effects.

Table 2: Types of Nanocarriers Used in Antifungal Therapy

Nanocarrier Type	Description	Applications in Antifungal Therapy
Liposomes	Biocompatible and biodegradable lipid-based vesicles that encapsulate drugs.	Used for the delivery of amphotericin B and fluconazole, enhancing their efficacy and reducing toxicity (41).
Niosomes	Non-ionic surfactant-based vesicles similar to liposomes, offer improved stability and lower toxicity.	Potential carriers for antifungal agents like clotrimazole, increasing solubility and bioavailability (42)
Polymeric Nanoparticles	Nanoparticles made from biodegradable polymers like PLGA, allow controlled release of drugs.	Effective for delivering itraconazole, improving therapeutic outcomes in fungal infections (43).
Solid Lipid Nanoparticles	Composed of solid lipids, providing a controlled release profile and enhanced stability.	Used to enhance the delivery of ketoconazole, increasing its antifungal activity (44).
Dendrimers	Highly branched, synthetic macromolecules with multiple functional groups for drug attachment.	Demonstrated efficacy in delivering antifungal agents like voriconazole, with targeted delivery to infected sites (45).
Nanocrystals	Colloidal dispersions of drug crystals, enhancing solubility and bioavailability.	Effective for antifungal drugs such as griseofulvin, showing improved dissolution rates (46).
Silica Nanoparticles	Porous silica materials that can encapsulate and release drugs in a controlled manner.	Utilized for delivering fluconazole, providing sustained release and enhancing antifungal effects (47).
Gold Nanoparticles	Nanosized gold particles with unique optical and electronic properties, enhance drug delivery.	Potential for use in combination therapies with antifungal agents, improving their efficacy against resistant strains (48).

4.2 Metal Nanoparticles for Antifungal Therapy

Metal nanoparticles, including silver (AgNP), gold (AuNP), and zinc oxide (ZnO), have been shown to have potent antibacterial properties against various fungal pathogens (26). These nanoparticles can inhibit fungal cells, induce oxidative stress, and prevent biofilm formation, making them particularly useful in anti-inflammatory treatments.

4.2.1 Silver Nanoparticles (AgNPs)

Silver nanoparticles have attracted widespread attention due to their broad-spectrum antimicrobial properties. AgNPs act as antibiotics by generating reactive oxygen species (ROS) that damage fungal cell walls and membranes, ultimately leading to cell death. Studies have shown that AgNPs are effective against Candida species, including resistant strains such as Candida auris.

4.2.2 Gold Nanoparticles (AuNPs)

Gold nanoparticles are effective and efficient options for treating fungal infections when used in conjunction with photothermal therapy. AuNPs can be functionalized with antibodies or targeting ligands, allowing them to bind specifically to fungal cells. When exposed to near-infrared (NIR) light, AuNPs generate local heat that kills fungal cells without damaging surrounding tissue.

4.2.3 Zinc Oxide Nanoparticles (ZnO NPs)

ZnO nanoparticles exhibit anti-inflammatory properties by increasing oxidative stress and inhibiting fungal cell walls. These nanoparticles are particularly effective against Candida and

Cryptococcus. Zinc oxide nanoparticles have also been shown to inhibit fungal biofilm formation, which is important in the treatment of persistent infections.

5. Mechanisms of Action of Nanoparticles in Antifungal Therapy

Nanoparticles exert their anti-inflammatory effects through different mechanisms depending on the type of nanomaterial used, including the production of reactive oxygen species (ROS), disruption of fungal cell membranes, and inhibition of biofilm formation (12).

5.1 Reactive Oxygen Species (ROS) Generation

Many metal nanoparticles, including silver and zinc oxide, produce reactive oxygen species when in contact with fungal pathogens. These ROS cause oxidative stress by damaging important cellular components such as lipids, proteins, and DNA. This causes the fungal cell wall and membrane to deteriorate, ultimately leading to cell death.

5.2 Disruption of Fungal Cell Membranes

Nanoparticles, particularly metal nanoparticles, can directly interact with fungal cell membranes, causing structural damage and loss of membrane integrity. This disrupts the normal function of the cell membrane, leading to leakage of cellular contents and eventual cell death.

5.3 Inhibition of Biofilm Formation

One of the biggest problems in treating fungal infections is the formation of biofilms, which protect fungal cells from attack by antibiotics and the immune system. Nanoparticles have been shown to inhibit biofilm formation by preventing fungal pathogens from adhering to surfaces and by disrupting the extracellular matrix that supports biofilm structure.

Table 3: Mechanisms of Action of Nanoparticles in Antifungal Therapy

Nanoparticle Type	Mechanism of Action	Examples of Use in Antifungal Therapy
Nanocrystals	Increase the solubility and bioavailability of poorly soluble antifungal drugs, enhancing their therapeutic action.	Applied for griseofulvin, improving its effectiveness against fungal infections (43).
Dendrimers	Possess multiple functional groups that can bind to fungal cells, enhancing the uptake of antifungal drugs.	Effective in delivering antifungal agents like itraconazole (45).
Gold Nanoparticles	Facilitate targeted drug delivery and enhance the permeability of fungal cell walls.	Used to improve the efficacy of antifungal agents like fluconazole (48).
Silver Nanoparticles	Release silver ions that disrupt cell membranes, inhibit biofilm formation and induce oxidative stress.	Effective against various fungi, including Candida albicans and Aspergillus niger (49).
Zinc Oxide Nanoparticles	Induce reactive oxygen species (ROS) production, leading to cell membrane damage and cell death.	Demonstrated antifungal activity against Candida species (49).
Chitosan Nanoparticles	Interact with fungal cell membranes, disrupting their integrity and facilitating drug entry.	Used as a carrier for antifungal drugs, enhancing their efficacy (50).
Magnetic Nanoparticles	Enable targeted delivery through an external magnetic field, increasing drug concentration at infection sites.	Applied in the targeted delivery of amphotericin B to infected tissues (51).
Silica Nanoparticles	Serve as carriers for antifungal agents, allowing controlled release and increased solubility.	Used for delivering azole antifungals, enhancing their therapeutic effects (52).

6. Challenges and Future Perspectives

Although nanotechnology holds promise for the diagnosis and treatment of fungal diseases, many challenges remain, including toxicity and biocompatibility, regulatory issues, and the need for large-scale clinical trials to validate the efficacy of nanotechnology-based therapies.

6.1 Toxicity and Biocompatibility

Although nanotechnology holds promise for the diagnosis and treatment of fungal diseases, many challenges remain, including toxicity and biocompatibility, regulatory issues, and the need for large-scale clinical trials to validate the efficacy of nanotechnology-based therapies.

6.3 Future Research Directions

Future research should focus on optimizing the design and synthesis of nanomaterials to improve their safety and performance. More research is needed, particularly on the long-term effects of exposure to nanoparticles and their potential interaction with the immune system (53). Large-scale clinical trials are also needed to validate the efficacy of nanotechnology-based treatments for fungal infections

6.2 Regulatory Challenges

The regulatory framework for nanomedicines has not yet been established, particularly concerning the long-term safety of nanomaterials. Regulatory agencies such as the FDA and EMA are working to develop guidelines for the approval of nanotechnology-based therapies (54). However, more research is needed to address specific issues arising from the use of nanomaterials in medicine.

CONCLUSION

Nanotechnology holds great promise in the diagnosis and treatment of fungal infections by addressing many limitations of antibiotic therapy. Nanosensors provide rapid and sensitive detection of fungal pathogens, while nanocarriers increase the bioavailability and efficacy of antibiotics. Metal nanoparticles such as silver and zinc oxide have potent anti-inflammatory effects through a variety of mechanisms, including ROS production and biofilm inhibition. Potential toxicity and control needs of the product are well-recognized. Future research should focus on developing better and more efficient nanomaterials, while also addressing regulatory and clinical issues related to their use. With continued innovation and collaboration between scientists, clinicians, and regulatory agencies, nanotechnology has the potential to revolutionize the management of fungal diseases.

REFERENCES

1. Brown, G. D., Denning, D. W., & Levitz, S. M. (2012). Tackling human fungal infections. Science, 336(6082), 647-651. (5)
2. Perfect, J. R. (2017). The antifungal pipeline: a reality check. Nature Reviews Drug Discovery, 16(9), 603-616. (24)
3. Perlin, D. S., Shor, E., Zhao, Y., & Ben-Ami, R. (2017). Update on antifungal drug resistance. Current Clinical Microbiology Reports, 4(2), 85-95. (25)
4. Pierce, C. G., Uppuluri, P., Tristan, A. R., Wormley, F. L., Jr., Mowat, E., Ramage, G., & Lopez-Ribot, J. L. (2017). A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nature Protocols, 3(9), 1494–1500. https://doi.org/10.1038/nprot.2008.141 (37)
5. Hamill, R. J. (2013). Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs, 73(9), 919-934. (14)
6. Rybak, J. M., Santos, M. C., & Williams, D. L. (2019). Nanotechnology for antifungal drug

delivery: Innovations and challenges. Antimicrobial Agents and Chemotherapy, 63(5), e02670-18. https://doi.org/10.1128/AAC.02670-18.

7. Arvanitis, M., Anagnostou, T., Fuchs, B. B., Caliendo, A. M., & Mylonakis, E. (2014). Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clinical Microbiology Reviews, 27(3), 490-526. (2)
8. Tasoglu, S., & Demirci, U. (2013). Advances in nanotechnology for personalized medicine. Advanced Materials, 25(13), 1737-1753. (30)
9. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. (1)
10. Zhou, H., & Wang, M. (2018). Nanosensors for diagnosis of fungal infections. Biosensors and Bioelectronics, 118, 169-178. (36)
11. Hamill, R. J. (2013). Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs, 73(9), 919-934. (14)
12. Jin, Y., Zhang, X., Li, Z., & Yang, J. (2021). Recent advances in the development of nanoparticles for antifungal therapy. Journal of Nanobiotechnology, 19(1), 100. https://doi.org/10.1186/s12951-021-00934-4 (38)
13. Chaudhary, P., Chhonker, Y. S., & Mishra, B. (2020). Dendrimer-based nanotherapeutics for drug delivery. Journal of Nanoscience and Nanotechnology, 20(5), 2876-2890. (7)
14. Singh, P., Sinha, N., & Singh, D. (2020). Nanoparticles as promising antifungal agents: A review. Journal of Drug Delivery Science and Technology, 57, 101748. https://doi.org/10.1016/j.jddst.2020.101748. (40)
15. Rai, M., Yadav, A., & Gade, A. (2012). Silver nanoparticles as a new generation of antimicrobials. Biotechnology Advances, 27(1), 76-83. (26)
16. Galdiero, S., Falanga, A., Cantisani, M., Tarallo, R., D'Oriano, V., & Galdiero, M. (2020). Silver nanoparticles as potential antifungal agents. Molecules, 25(20), 4695. (12)
17. Jung, S., Bae, K., Kang, H., & Lee, J. (2019). Gold nanorods for photothermal therapy in fungal infections. Nanomedicine, 14(8), 1003-1011. (16)
18. Kumar, S., Gupta, S., & Mittal, A. (2020). ZnO nanoparticles as antifungal agents: mechanisms of action. Materials Science and Engineering: C, 108, 110489. (18)
19. Smith, A. M., & Nie, S. (2019). Quantum dots for ultrasensitive molecular diagnostic assays. Trends in Biotechnology, 37(1), 99-112. (28)
20. Rautela, I., & Rani, J. (2019). ZnO and TiO2 nanoparticles for antifungal treatments: Potential applications and mechanisms of action. Frontiers in Microbiology, 10, 171.
21. Adaeze Linda Onugwu a, Chinekwu Sherridan Nwagwu a, Obinna, Adaeze Sabastine Onugwu b Chidiebere Echezona., A Nanotechnology-based drug delivery system for the treatment of anterior segment eye diseases., Volume 354, February 2023, Pages 465-488. (55)
22. Ravina, Subodh Soni, Manjeet Chahar, Minakshi Prasad & Hari Mohan., Nanointerventions for the Detection of Fungal Livestock Diseases., Springer, Singapore 12 July 2024 https://doi.org/10.1007/978-981-16-1610-5_7. (56)
23. Azzouz, A., Khabbaz, H., Abdel-Khalek, A., & Abou-Salama, A. (2020). Detection of Candida species using graphene oxide nanosheets. Biosensors, 10(2), 23-29. (3)
24. Sun, H., Zhou, X., & Zhang, Y. (2021). Quantum dots in biosensing and bioimaging

applications for fungal infections. Journal of Biotechnology, 320, 64-72. (29)

25. Pinto, S. S., Pereira, M. M., & Ferreira, M. M. (2015). Advances in liposomal formulations for the treatment of fungal infections. International Journal of Pharmaceutics, 494(1), 37-48. https://doi.org/10.1016/j.ijpharm.2015.07.020
26. Nayak, A., Ranjan, S., & Das, D. (2020). Niosomes: A promising nanocarrier for antifungal therapy. Journal of Nanomedicine Research, 8(1), 1-8. https://doi.org/10.15406/jnmr.2020.08.00351
27. Mishra, P. K., Singh, S., & Singh, D. (2021). Nanoparticle-mediated delivery of antifungal agents: Challenges and future perspectives. Nanotechnology Reviews, 10(1), 265-288.
28. Kumar, A., Prakash, A., & Gupta, S. (2022). Nanocarrier systems for the enhanced delivery of ketoconazole: A review. Journal of Controlled Release, 351, 382-395. https://doi.org/10.1016/j.jconrel.2022.06.023 (44)
29. Chatterjee, B., Bhandari, S., & Pande, A. (2019). Targeted delivery of voriconazole using nanocarriers: A promising approach for antifungal therapy. Nanomedicine: Nanotechnology, Biology and Medicine, 19, 123-130. https://doi.org/10.1016/j.nano.2019.05.003 (45)
30. Dhanik, A., Prasad, B., & Kumar, P. (2021). Nanoparticle-based formulations for enhancing the dissolution and bioavailability of griseofulvin. International Journal of Nanomedicine, 16, 1731-1745. https://doi.org/10.2147/IJN.S295152. (45)
31. Zhou, H., Li, Y., & Chen, H. (2023). Development of a novel nanocarrier for the sustained release of fluconazole: Implications for antifungal therapy. Colloids and Surfaces B: Biointerfaces, 214, 112485. https://doi.org/10.1016/j.colsurfb.2022.112485. (47)
32. Huang, X., Jain, P. K., El-Sayed, I. H., & El-Sayed, M. A. (2017). Gold nanoparticles: Interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine, 2(5), 681-693. (15)
33. Khan, M. I., Shah, S. Z., & Ahmed, N. (2019). Antifungal efficacy of novel nanoparticles against Candida albicans and Aspergillus niger. Journal of Mycology and Medical, 29(1), 47-54. https://doi.org/10.1016/j.mycmed.2018.09.005 (49)
34. Sharma, A., Gupta, V., & Singh, R. (2021). Nanotechnology in antifungal therapy: Potential for combination therapies to combat resistant strains. Frontiers in Microbiology, 12, 663237. https://doi.org/10.3389/fmicb.2021.663237. (48)
35. Alves, M. J., Costa, M. P., & Pereira, M. C. (2020). Nanoparticle carriers for antifungal drug delivery: Enhancing efficacy and reducing toxicity. Journal of Drug Delivery Science and Technology, 56, 101445. https://doi.org/10.1016/j.jddst.2020.101445. (50)
36. Zhou, H., Li, Y., & Chen, H. (2023). Targeted delivery of amphotericin B using multifunctional nanoparticles for enhanced antifungal therapy. Colloids and Surfaces B: Biointerfaces, 220, 112924. https://doi.org/10.1016/j.colsurfb.2023.112924. (51)
37. Dhanik, A., Prasad, B., & Kumar, P. (2021). Nanoparticle-based delivery systems for azole antifungals: Enhancing therapeutic effects and reducing resistance. Journal of Nanomedicine Research, 9(4), 1-10. https://doi.org/10.15406/jnmr.2021.09.00351. (52)

38. Maurer, F. K., Wilhelm, S., & Hirn, S. (2016). A critical review on the biocompatibility of engineered nanoparticles and their uptake in tissue-specific in vivo models. Nanoscale, 8(17), 9857-9870. (21)
39. Bobo, D., Robinson, K. J., Islam, J., & Woodworth, G. F. (2016). Nanoparticle-mediated drug delivery: A review of the current and future applications. Frontiers in Pharmacology, 7, 391. https://doi.org/10.3389/fphar.2016.00391.
40. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48.
41. Arvanitis, M., Anagnostou, T., Fuchs, B. B., Caliendo, A. M., & Mylonakis, E. (2014). Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clinical Microbiology Reviews, 27(3), 490-526.
42. Azzouz, A., Khabbaz, H., Abdel-Khalek, A., & Abou-Salama, A. (2020). Detection of Candida species using graphene oxide nanosheets. Biosensors, 10(2), 23-29.
43. Bhattacharjee, S., Rengasamy, M., & Kuppusamy, P. (2021). Gold nanoparticles for fungal detection: Advances and perspectives. Journal of Nanobiotechnology, 19(1), 23-33.
44. Brown, G. D., Denning, D. W., & Levitz, S. M. (2012). Tackling human fungal infections. Science, 336(6082), 647-651.
45. Campuzano, S., Pedrero, M., & Pingarrón, J. M. (2018). Carbon nanotube-based biosensors for detection of fungal infections. Electroanalysis, 30(1), 143-155.
46. Chaudhary, P., Chhonker, Y. S., & Mishra, B. (2020). Dendrimer-based nanotherapeutics for drug delivery. Journal of Nanoscience and Nanotechnology, 20(5), 2876-2890.
47. Chen, Y., Li, X., Zhang, J., & Zhang, X. (2021). Metal-organic frameworks as photosensitizers for photodynamic therapy. Advanced Healthcare Materials, 10(3), 2001121.
48. Dai, T., Garcia, B., Murray, C. K., Vrahas, M. S., Hamblin, M. R., & Tegos, G. P. (2018). Photodynamic therapy for invasive fungal infections: current perspectives. Clinical Microbiology Reviews, 31(3), e00085-17.
49. Denning, D. W., & Bromley, M. J. (2015). How to bolster the antifungal pipeline. Science, 347(6229), 1414-1416.
50. Fadeel, B., & Alex, T. (2019). In it for the long haul: regulatory challenges and opportunities for nanomedicine. ACS Nano, 13(9), 9742-9748.
51. Galdiero, S., Falanga, A., Cantisani, M., Tarallo, R., D'Oriano, V., & Galdiero, M. (2020). Silver nanoparticles as potential antifungal agents. Molecules, 25(20), 4695.
52. Gow, N. A. R., & Netea, M. G. (2016). Medical mycology and fungal immunology: New research perspectives addressing a major world health challenge. Philosophical Transactions of the Royal Society B: Biological Sciences, 371(1709), 20150475.
53. Hamill, R. J. (2013). Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs, 73(9), 919-934.
54. Huang, X., Jain, P. K., El-Sayed, I. H., & El-Sayed, M. A. (2017). Gold nanoparticles: Interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine, 2(5), 681-693.
55. Jung, S., Bae, K., Kang, H., & Lee, J. (2019). Gold nanorods for photothermal therapy in fungal infections. Nanomedicine, 14(8), 1003-1011.

HOW TO CITE: Priyanka Kachave*, Anuja Pharne, Vedanti Dawange, Nanotechnology-Based Diagnosis and Treatment of Fungal Infections, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 6, 5654-5665. https://doi.org/10.5281/zenodo.15767356